Skip to main content

ZLAB

Stock
Health Care
Biotechnology

Performance overview

ZLAB Price
Price Chart

Forward-looking statistics

Beta
1.25
Risk
58.76%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

Company info

SectorHealth Care
IndustryBiotechnology
Employees1K
Market cap$2.0B

Fundamentals

Enterprise value$37.4B
Revenue$418.3M
Revenue per employee
Profit margin-60.26%
Debt to equity23.72

Security info

ExchangeNASDAQ
Type of shareADR
Earnings per share (EPS)-$2.50
Dividend per share
Revenue per share$4.12
Avg trading volume (30 day)$33M
Avg trading volume (10 day)$25M
Put-call ratio

Macro factor sensitivity

Growth-2.4
Credit+4.0
Liquidity+1.3
Inflation-6.2
Commodities-1.3
Interest Rates-2.8

Valuation

Dividend yield0.00%
PEG Ratio-19.06
Price to sales9.61
P/E Ratio-19.06
Enterprise Value to Revenue89.33
Price to book4.87

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day
Ex. dividend day

News

Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Zai Lab Limited (ZLAB) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research (May 8, 2025)
Top 5 Health Care Stocks That Are Preparing To Pump In February

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Benzinga (February 9, 2024)
Jefferies' Michael Yee explains his top biotech picks: VRTX, FATE, ZLAB

Michael Yee, Jefferies, joins 'The Exchange' to discuss what's driving the biotech bounce and his top picks. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi  » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC Turn to CNBC TV for the latest stock market news and analysis.

CNBC Television (March 29, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free